SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug Lakin who started this subject3/6/2002 3:47:32 PM
From: Ian@SI  Read Replies (1) of 1321
 
2:27 (Dow Jones) IMS Health (RX) reported that U.S. sales of QLT Inc.'s (QLTI) anti-blindness drug, Visudyne, came in at $12 million in January,according to BMO Nesbitt Burns analyst Christine Charette. If correct, that would mean Visudyne sales rose 45% from January 2001, she said. But the numbers could be even better. Charette noted that IMS estimates for Visudyne sales were lower in three out of four quarters last year, and said it's likely January 2002 sales were also "underestimated." On Nasdaq, QLT shares are up 9% at $20.27. (AMG)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News